According to the most recent data available, inherited neuromuscular diseases affect only 0.048% of the population, a figure that explains some of the clinical and logistical difficulty of studying them well. Patients, who may already experience symptoms like progressive muscle weakness, mobility loss, and fatigue from respiratory or cardiac complications, are usually scattered across the country and may have difficulty participating in clinical research even when they have strong motivation to do so. Continuous monitoring with wearable devices helps to alleviate some of the logistical challenges of studying this disease group.
This blog will explain:
Rare disease research, including neuromuscular disease, can be difficult to study because there are fewer patients with the disease and those who are eligible may live nowhere near a planned study site. Neuromuscular disease illustrates this well, since the category includes distinct conditions such as Duchenne and Becker muscular dystrophy, spinal muscular atrophy, amyotrophic lateral sclerosis, myotonic dystrophy, and myasthenia gravis, each with its own genetic cause, disease course, and small patient population. Scarcity of patients often limits statistical power from the outset and makes every enrolled patient disproportionately important to a study's success.
Geographic distribution means that sponsors must plan differently for rare disease clinical trials, because frequent in-person visits may be near impossible for some families. Researchers are left balancing two competing pressures: the need for rigorous, frequent assessment to track a progressive disease, and the practical limits of what a small, scattered patient population can sustain over the course of a multi-year trial.
The daily reality of living with a neuromuscular disease shapes what a family can reasonably manage on top of standard care, let alone a clinical trial. For example, Duchenne muscular dystrophy progressively weakens skeletal muscle, and for many patients that includes the muscles needed to transfer from a wheelchair to a car, sit upright for an extended car ride, or tolerate a long day of travel without significant fatigue. As the disease advances, cardiac and respiratory complications add another layer of risk to travel itself, since a family may need to coordinate portable ventilation equipment or monitor for signs of distress along the way.
Spinal muscular atrophy presents a different version of the same problem. Patients with more severe forms of SMA often depend on specialized mobility equipment and may have limited head and trunk control, both of which complicate transportation and make a standard clinic visit physically demanding. Retaining patients with these conditions can be challenging due to the logistical challenges of participating alongside the demands of daily caregiving.
Addressing the research and patient burden challenges outlined above requires an approach to data collection that does not depend on bringing patients into a clinic to capture meaningful information. For example, rather than asking patients to travel for a single assessment every few months, continuous monitoring with wearable devices allows sponsors to collect data on mobility, heart rate, respiratory patterns, and activity levels while patients remain at home.
This shifts the clinical picture from an isolated window to a continuous record of how a patient is doing between visits. Fewer required in-person visits can also reduce the burden that drives patients to drop out of a study, which matters enormously in a therapeutic area where every enrolled patient is difficult to replace. Contact Vivalink if your organization needs a remote monitoring solution built for the unique demands of rare disease research, from reducing patient travel burden to capturing continuous data between visits.